Let's break down RPG Life Sciences Limited (RPGLIFE) — from its financial performance to how the market is valuing the stock.
RPG Life Sciences Limited Revenue Trend
RPG Life Sciences Limited's top line grew 13.0% to ₹666 Cr in FY2025, compared to ₹589 Cr in FY2024.
A 10.6% CAGR over 10 years puts RPG Life Sciences Limited in solid growth territory. The top line went from ₹242 Cr to ₹666 Cr in that span.
In terms of scale, RPG Life Sciences Limited's ₹666 Cr in annual revenue positions it as a smaller pharmaceuticals company.
It's been 6 years of continuous revenue growth for RPG Life Sciences Limited — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹666 Cr | +13.0% |
| FY2024 | ₹589 Cr | +13.8% |
| FY2023 | ₹518 Cr | +16.8% |
| FY2022 | ₹443 Cr | +13.6% |
| FY2021 | ₹390 Cr | — |
View RPG Life Sciences Limited's full 10-year revenue trend with CAGR analysis →
RPG Life Sciences Limited Profitability
Profitability strengthened with net income of ₹183 Cr in FY2025, 109.0% higher than FY2024.
The company squeezed out better margins in FY2025, with net margin at 27.5% versus 14.9% in FY2024.
On a per-share basis, diluted earnings were ₹110.80 in FY2025 versus ₹53.01 in FY2024.
Is RPG Life Sciences Limited Undervalued
The P/E Ratio approach puts RPG Life Sciences Limited's intrinsic value at ₹2,732, a 24.3% upside from the current market price.
RPG Life Sciences Limited shares are currently trading at ₹2,198.20.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹2,732 | 24.3% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for RPG Life Sciences Limited with detailed assumptions →
RPG Life Sciences Limited Shareholding Pattern
Promoter holding has remained stable at 73.0% over the past 4 quarters, indicating confidence in the company's direction.
FII holding stands at 0.9%, down from 1.4% in the year-ago quarter.
As of March 2026, DIIs own 7.5% of the company — up from 6.5% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 73.0% | 0.9% | 7.5% | 18.7% |
| Dec 2025 | 73.0% | 1.0% | 7.0% | 19.0% |
| Sep 2025 | 73.0% | 1.1% | 6.7% | 19.2% |
| Jun 2025 | 73.0% | 1.4% | 6.5% | 19.2% |
Track quarterly shareholding changes for RPG Life Sciences Limited →
RPG Life Sciences Limited Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹6.58B (up 28.3% YoY from ₹5.13B).
Top categories: Property, Plant & Equipment (25.1%), Cash & ST Investments (23.5%), Other Assets (20.5%).
Of the ₹6.58B in liabilities and equity, 80.7% is shareholder equity, 0.0% is interest-bearing debt, and 19.3% is operating liabilities. Notable shift: Equity is up 41.5% YoY (₹3.75B → ₹5.31B).
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 1.55B |
| Receivables | 867.60M |
| Inventories | 929.80M |
| Property, Plant & Equipment | 1.65B |
| Investments | 10.10M |
| Intangibles & Goodwill | 227.60M |
| Other Assets | 1.35B |
| Category | Value |
|---|---|
| Equity | 5.31B |
| Trade Payables | 793.90M |
| Other Liabilities | 478.90M |
RPG Life Sciences Limited — The Bottom Line
Bringing the key threads together for RPG Life Sciences Limited (RPGLIFE) as a pharmaceuticals investment opportunity.
Revenue of ₹666 Cr in FY2025, up 13.0% year-over-year.
Long-term revenue has been compounding at 10.6% annually over 10 years.
The company is profitable, with a net margin of 27.5% and net income of ₹183 Cr.
The P/E Ratio model implies 24.3% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Craytheon's full analysis of RPG Life Sciences Limited goes deeper: three valuation models, growth metrics, and 10 years of financial data.